REG - Aptamer Group PLC - Commercial Trading Update

AptamerAnnouncement

06/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241106:nRSF0805La&default-theme=true

RNS Number : 0805L  Aptamer Group PLC  06 November 2024

   6 November 2024

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Commercial Trading Update

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, is pleased to provide an
update on contracts signed since its financial year ended 30 June 2024.

 

Aptamer has secured new contracts worth up to £471,000 continuing the
positive commercial traction achieved during the last quarter of the previous
financial year. These contracts include multiple agreements, including two
from top 20 and one from a top 5 global pharmaceutical companies, totalling up
to £340,000. These projects are aimed at developing Optimers as critical
reagents to support active clinical development programmes and facilitate the
analysis of novel therapeutics.

 

A significant proportion of these deals involve repeat customers who are
advancing Aptamer's binders within their internal pipelines, with some
signalling intent for long-term licensing revenues. This ongoing traction
highlights Aptamer's role in supporting key industry players and reinforces
our position as a key player in the market.

These new contracts illustrate Aptamer's increasing commercial traction and
the Group's ability to secure repeat business from top pharmaceutical
companies. Aptamer now has booked revenue contracts of up to c. £1.2m to
recognise throughout FY25 (Jun 25 year-end) and an increased sales pipeline
from £2.1m in July 2024 to £4.0m as of today.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group said: "Following the
fundraise in August 2024, I am pleased to report that the sustained focus of
our commercial team continues to bear fruit. We are advancing steadily towards
our revenue and potential licensing goals for FY 25 with the best part of 7
months left in the financial year. Revenue generation and increased income
from licensing form a pivotal component of the Group's strategy to deliver
shareholder value and I look forward to updating you on future contracts and
key project updates." 

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Adam Dawes 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group plc

 

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion.

 

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTQKPBBBBDBPDK